Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Cohn

Showing results (491-500 of 612) with videos related to

Pageof 62
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 20, 2016
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group databaseDaniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Journal of the National Cancer Institute|November 9, 2017
Evaluation of Genetic Predisposition for MYCN-Amplified NeuroblastomaEric A Hungate, Mark A Applebaum, Andrew D Skol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group projectKieuhoa T Vo, Katherine K Matthay, John Neuhaus, et al.
Pediatric Blood & Cancer|July 22, 2014
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group projectHolly J Meany, Wendy B London, Peter F Ambros, et al.
Pediatric Blood & Cancer|June 2, 2025
Long-Term Outcome of Young Infants With Suspected Neuroblastoma following Observation as Primary Therapy: A Report From the Children's Oncology GroupHetal Dholaria, Arlene Naranjo, Fan F Zhang, et al.
Cancer|June 4, 2008
External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trialDeborah T Blumenthal, Cathryn Rankin, Harmon J Eyre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Cancer|October 15, 2013
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trialCharles S Fuchs, Marwan Fakih, Lee Schwartzberg, et al.
Pediatric Blood & Cancer|September 11, 2018
Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastomaElizabeth A Sokol, Roger Engelmann, Wenjun Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of ageDenah R Taggart, Wendy B London, Mary Lou Schmidt, et al.
Pageof 62

Showing results (491-500 of 612) with videos related to

Sort By:
Pageof 62
European Journal of Cancer (Oxford, England : 1990)|July 20, 2016
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group databaseDaniel A Morgenstern, Wendy B London, Derek Stephens, et al.
Journal of the National Cancer Institute|November 9, 2017
Evaluation of Genetic Predisposition for MYCN-Amplified NeuroblastomaEric A Hungate, Mark A Applebaum, Andrew D Skol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group projectKieuhoa T Vo, Katherine K Matthay, John Neuhaus, et al.
Pediatric Blood & Cancer|July 22, 2014
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group projectHolly J Meany, Wendy B London, Peter F Ambros, et al.
Pediatric Blood & Cancer|June 2, 2025
Long-Term Outcome of Young Infants With Suspected Neuroblastoma following Observation as Primary Therapy: A Report From the Children's Oncology GroupHetal Dholaria, Arlene Naranjo, Fan F Zhang, et al.
Cancer|June 4, 2008
External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trialDeborah T Blumenthal, Cathryn Rankin, Harmon J Eyre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Cancer|October 15, 2013
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trialCharles S Fuchs, Marwan Fakih, Lee Schwartzberg, et al.
Pediatric Blood & Cancer|September 11, 2018
Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastomaElizabeth A Sokol, Roger Engelmann, Wenjun Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of ageDenah R Taggart, Wendy B London, Mary Lou Schmidt, et al.
Pageof 62